Market research
BHC Bausch Health Companies Inc
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 7.5
- Dividend yield
- Not available
- Beta
- 0.38
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA0717341071
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 7.5
- Dividend yield
- Not available
- Beta
- 0.38
About
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BHC discussion.
5 years, 4 months ago
Bausch Health Companies Inc is currently in a long term uptrend where the price is trading 9.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Bausch Health Companies Inc's total revenue sank by 0.5% to $2B since the same quarter in the previous year.
Its net income has increased by 89.9% to $-153M since the same quarter in the previous year.
Finally, its free cash flow grew by 108.1% to $310M since the same quarter in the previous year.
Based on the above factors, Bausch Health Companies Inc gets an overall score of 4/5.